Abstract
A cardiac hypertrophy is defined as an increase in heart mass which may either be beneficial (physiological hypertrophy) or detrimental (pathological hypertrophy). This study was undertaken to establish the role of different protein kinase-C (PKC) isoforms in the regulation of cardiac adaptation during two types of cardiac hypertrophy. Phosphorylation of specific PKC-isoforms and expression of their downstream proteins were studied during physiological and pathological hypertrophy in 24 week male Balb/c mice (Mus musculus) models, by reverse transcriptase-PCR, western blot analysis and M-mode echocardiography for cardiac function analysis. PKC-δ was significantly induced during pathological hypertrophy while PKC-α was exclusively activated during physiological hypertrophy in our study. PKC-δ activation during pathological hypertrophy resulted in cardiomyocyte apoptosis leading to compromised cardiac function and on the other hand, activation of PKC-α during physiological hypertrophy promoted cardiomyocyte growth but down regulated cellular apoptotic load resulting in improved cardiac function. Reversal in PKC-isoform with induced activation of PKC-δ and simultaneous inhibition of phospho-PKC-α resulted in an efficient myocardium to deteriorate considerably resulting in compromised cardiac function during physiological hypertrophy via augmentation of apoptotic and fibrotic load. This is the first report where PKC-α and -δ have been shown to play crucial role in cardiac adaptation during physiological and pathological hypertrophy respectively thereby rendering compromised cardiac function to an otherwise efficient heart by conditional reversal of their activation.
Highlights
Cardiac hypertrophy is defined as an increase in cardiac mass and two forms of cardiac hypertrophy viz. physiological and pathological are currently recognized
Significant increase in expression of Atrial natriuretic factor (ANF) and b Myosin heavy chain (b-MHC) in group exercise withdrawn animals (ER) (1.9760.12-fold for ANF and 2.0260.12-fold for b-MHC) compared to E, whereas, exercise training in pathological hypertrophy group showed significant down regulation in expression of both these hypertrophy marker genes (ANF: 2.4460.03-fold and b-MHC: 2.1460.02fold in HX compared to H; Figure 1C, Figure S3)
ribosomal protein L-32 (RPL32) was used as loading control. (C) Western blot analyses showing changes in expression of phosphorylated and total protein kinase-C (PKC)-d and PKC-a in exercise withdrawn animals (ER) rested for different time periods
Summary
Cardiac hypertrophy is defined as an increase in cardiac mass and two forms of cardiac hypertrophy viz. physiological and pathological are currently recognized. Physiological increase in cardiac mass is considered to be an adaptive beneficial response which occurs normally during development, pregnancy and in response to sustained exercise [1] that enhances normal cardiac structure and normal or improved cardiac function with no evidence of myocyte apoptosis [2,3]. Several researchers have shown cardio-protective role of regular exercise in individuals suffering from cardiovascular diseases [15] and endurance training could convert pathological cardiac hypertrophy into physiological form with improved cardiac performances [16]. Our study for the first time has identified specific isoforms of PKC associated to either physiological or pathological hypertrophy and addressed the mechanism of such diverse cardiac adaptation by PKC-isoform switch
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.